Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

The effect of glucagon-like peptide-1 (GLP-1) receptor agonists on substance use disorder (SUD)-related behavioural effects of drugs and alcohol: A systematic review

Research output: Contribution to journalReviewpeer-review

  1. Post-oral fat-induced satiation is mediated by endogenous CCK and GLP-1 in a fat self-administration mouse model

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Association between habitual sleep duration/quality and appetite markers in individuals with obesity

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Novel GLP-1/GLP-2 co-agonists display marked effects on gut volume and improves glycemic control in mice

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Decreased spontaneous activity in AMPK α2 muscle specific kinase dead mice is not caused by changes in brain dopamine metabolism

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. The glucagon-like peptide 1 (GLP-1) receptor agonist exendin-4 reduces cocaine self-administration in mice

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Virtual reality as therapy in pscyhiatry

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Effects of ketogenic diet and ketone monoester supplement on acute alcohol withdrawal symptoms in male mice

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Exploring Movement Impairments in Patients With Parkinson's Disease Using the Microsoft Kinect Sensor: A Feasibility Study

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Glucagon-like-peptide-1 (GLP-1)-receptor agonists have been proposed as putative treatment for substance use disorders (SUD). The objective of this systematic review is to characterize the effects of GLP-1-receptor agonists on SUD-related behavioural effects of drugs, nicotine, and alcohol. The review was performed according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). A search was performed in PubMed and EMBASE on June 16, 2018. The inclusion criteria were primary studies investigating the use of GLP-1-receptor agonists on behavioural endpoints related to SUD. Seventeen studies were included, investigating the effect of the GLP-1-receptor agonists exendin-4, fluoro-exendin-4, liraglutide, AC3174 and GLP-1 (7-36) on SUD-related behavioural effects of ethanol, cocaine, amphetamine, and/or nicotine. All studies used rodents as subjects. Nine of the studies dealt with ethanol, six with cocaine, two with amphetamine, and two with nicotine. Most studies investigated acute treatment effects, finding a significant effect in all but one experiment. A few studies investigated more chronic effects on ethanol. All the studies reported sustained effects. Eleven studies tested more than one dose, finding a dose-related response in ten out of thirteen experiments. Six studies report a central effect through intra-cerebral administration or by using mice in which the central GLP-1-receptors had been inactivated. In conclusion, a solid body of evidence documents acute effects of GLP-1-receptor agonist treatment on behavioural effects of alcohol, nicotine, amphetamine and cocaine. Documentation of effect of more chronic GLP-1-receptor stimulation on these behaviours is limited.

Original languageEnglish
JournalPhysiology & Behavior
Volume206
Pages (from-to)232-242
Number of pages11
ISSN0031-9384
DOIs
Publication statusPublished - 1 Jul 2019

ID: 59120512